Crinetics Pharmaceuticals Stock Earnings Reports

Crinetics reported a constructive first quarter 2026 focused on the commercial launch of Palsonify and continued clinical development across a deep, internally‑discovered pipeline. Key commercial highlights: 232 new patient enrollment forms in Q1 and $10.3M in net product revenue (total revenue $10.7M); ~263 unique prescribers as of March 31; ~70% of patients on therapy had meaningful reimbursement at quarter end and management expects >75% coverage by end of Q3 2026; treatment‑naive patients represented ~15% of Q1 enrollments, an encouraging sign of first‑line uptake; early signals of re‑engagement of patients who previously discontinued therapy. Clinical and pipeline highlights: four major trials actively running (including Phase III programs in carcinoid syndrome, adult CAH, pediatric CAH and Cushing's), ongoing dose‑escalation and expansion planning for 9682, and additional presentations/real‑world data planned at major meetings (Endocrine Society, AACE). Financial and corporate position: R&D spend increased to $100.1M in Q1 (driven by trial ramp and new pediatric study), SG&A ~$50.8M; cash, cash equivalents and investments of $1.3B as of quarter end; full‑year 2026 GAAP operating expense guidance maintained at $600–650M (non‑GAAP $480–520M); company projects cash runway into 2030. International progress: EC approval of the MAA, Japan NDA submission by SKK, and MAA submission in Brazil; management will pursue a disciplined, market‑by‑market international rollout. Management emphasized strong real‑world feedback, low discontinuation expectations, continued compounding patient growth, and disciplined investment given changing global pricing and access dynamics. Risks called out include forward‑looking assumptions, payer dynamics, and the usual clinical and regulatory uncertainties.